Change the future of personal diagnostics

Bringing Nobel Prize winning molecular diagnostics
from lab to PoC and patients

Investment Highlights

Revolution in Point of Care diagnostics – combines laboratory accuracy with OTC convenience


Disruptive market approach – opens previously laboratory-based markets for self-testing


Break-even by 2020 and €100 million revenues by 2022 – exit opportunities for investors


Operating in highly attractive markets – high growth with strong, unmatched diagnostic need


First product launch in 2018 for Sexually Transmitted Disease (STD) – far more in pipeline


Strong management and enthusiastic R&D team – strong industry and academic credentials


Our first product is for STDs – but we can quickly address
any disease detected from DNA or RNA

Sexually Transmitted Disease (STD) diagnostics market 2017

Sexually Transmitted Disease (STD) – 357 million cases annually of most common infections.


New products in our pipeline 

Influenza – IVD market €1.9 billion in 2015 and €3.3 billion by 2024 with CAGR 6.4%


Hospital acquired diseases, MRSA – diagnostics market size €0.5 billion, CAGR 11.6%, 53 million infected people


Enteric diseases – IVD market €3.1 billion 2012 and €3.6 billion by 2019 CAGR 2.4 %


Anthrax – the global biodefense against anthrax valued at over €2.0 billion already in 2013


Malaria – 214m new cases worldwide, level of spending €2.5 billion, annual funding €8.7 billion by 2030.

Mycobacterium tuberculosis – 9.6 million new infections


Broadly applicable in other fields – veterinary, food safety, detection of biological threats, contamination


Our first product: we address the shortcomings of STD testing with our revolutionary technology

Accuracy, Convenience and Scalability – platform for future detection of all STD‘s in one test

Break-even: we are planning profitability for 2020 – new products will fuel growth

Why invest into Selfdiagnostics today?

  • Proprietary, patented technology – can detect anything with DNA/RNA, highly scalable

  • Massive growth potential through broad pipeline in existing and new market segments

  • Annual revenues of up to €100 million within five years from proprietary pipeline

  • Realistic projections – first market launch in 2018, all R&D milestones were met so far

  • Strong management team with complementary mix of startup and industry experience

  • Break-even within three years provides attractive first exit opportunity to investors

All inquiries please contact:
Founding CEO – Marko Lehes

marko.lehes[at]selfdiagnostics.com
+372 521 5105
Skype: mlehes

Next round investment of €11 million to scale-up production